Skip to main content
LENZ Therapeutics, Inc. logo

LENZ Therapeutics, Inc. — Investor Relations & Filings

Ticker · LENZ ISIN · US38870X1046 US Manufacturing
Open in API
Filings indexed 329 across all filing types
Latest filing 2024-02-09 Regulatory Filings
Country US United States of America
Listing US LENZ

About LENZ Therapeutics, Inc.

https://lenz-tx.com/

LENZ Therapeutics, Inc. is a late-stage pharmaceutical company focused on developing and commercializing ophthalmic therapies to improve vision. Its primary product is VIZZ™ (aceclidine ophthalmic solution) 1.44%, an FDA-approved eye drop for the treatment of presbyopia, the age-related loss of near vision. VIZZ is the first aceclidine-based therapy for this condition, which affects an estimated 1.8 billion people globally. The product is designed to restore near vision, providing a pharmaceutical alternative to reading glasses for a broad patient population.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2024
Regulatory Filings Classification · 95% confidence The document is a correspondence letter from a law firm to the SEC regarding comments on a Registration Statement on Form S-4, which is related to a merger transaction. The letter addresses SEC staff comments and responses, and mentions filing an Amendment No. 3 to the Registration Statement. The content is focused on regulatory communication about a merger-related filing, not the merger document itself or a full report. This type of document is best classified under Regulatory Filings (RNS) as it is a regulatory correspondence and does not contain the merger filing or financial data itself.
2024-02-09 English
S-4/A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is an SEC filing identified as an Amendment No. 3 to Form S-4, which is a registration statement filed under the Securities Act of 1933. The text includes detailed information about a proposed merger between Graphite Bio, Inc. and Lenz Therapeutics, Inc., including the merger agreement, exchange ratio, private placement financing, stockholder meeting details, and proxy solicitation for voting on merger-related proposals. The document is a preliminary proxy statement/prospectus related to the merger transaction, containing detailed information for stockholders to make informed voting decisions. This type of document is classified as a Proxy Solicitation & Information Statement (PSI) because it is sent to shareholders to provide information and request votes for the merger and related corporate actions. The document is not a full annual report, earnings release, or other financial report, but rather a merger-related proxy statement with solicitation materials.
2024-02-09 English
Regulatory Filings 2024
Regulatory Filings
2024-02-09 English
Regulatory Filings 2024
Regulatory Filings Classification · 95% confidence The document is a letter from a law firm to the SEC responding to comments on a Registration Statement on Form S-4 filed by Graphite Bio, Inc. The letter discusses amendments to the Registration Statement, responses to SEC staff comments, and revisions to disclosures related to a merger and material contracts. The presence of references to Form S-4, detailed responses to SEC comments, and amendments to a registration statement indicate this is a regulatory filing related to a merger transaction. The document is not the registration statement itself but a correspondence responding to SEC comments on the filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory correspondence and filings that do not fit other specific categories.
2024-02-05 English
S-4/A
Merger & Acquisition Classification · 95% confidence The document is an SEC filing titled 'AMENDMENT NO. 2 to FORM S-4 REGISTRATION STATEMENT' filed by Graphite Bio, Inc. The Form S-4 is a registration statement used for securities issued in connection with mergers and acquisitions. The text discusses a proposed merger, details of the merger agreement, stockholder meeting for approval of the merger, issuance of shares, reverse stock split, and related corporate actions. It also references a private placement (PIPE) concurrent with the merger. The document is a detailed merger-related filing, not a proxy statement alone, nor a simple announcement. It is a regulatory filing related to a merger transaction, specifically a Form S-4 amendment. According to the filing definitions, merger-related registration statements and communications fall under 'Merger & Acquisition (MA)' filings. Therefore, the correct classification is 'MA' with high confidence.
2024-02-05 English
Major Shareholding Notification 2024
Major Shareholding Notification
2024-02-05 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.